主页 > 生命科学 >
【medical-news】血液化验能检测阿尔茨海默氏病？
Blood Test for Alzheimer's Disease?
血液化验能检测阿尔茨海默氏病？
ScienceDaily (Jan. 7, 2011) — Scientists from the Florida campus of The Scripps Research Institute, have developed a novel technology that is able to detect the presence of immune molecules specific to Alzheimer's disease in patients' blood samples. While still preliminary, the findings offer clear proof that this breakthrough technology could be used in the development of biomarkers for a range of human diseases.
从佛罗里达州斯克里普斯研究所的校园，科学家们已经开发出一种新技术，能够检测出特定的阿尔茨海默氏症患者的血液样本疾病的免疫分子的存在。虽然还是初步的，提供明确的调查结果证明，这种突破性技术可开发的生物标志物用于人类疾病的范围。
The study, led by Scripps Research Professor Thomas Kodadek, Ph.D., is published in the January 7, 2011 edition of the journal Cell.
这项研究是由斯克里普斯研究教授托马斯Kodadek博士的领导下，发表在2011年1月7日的Cell杂志编辑。
Traditionally, antigens -- a substance such as a protein from a virus or bacteria that stimulates an immune response -- have been necessary for the discovery of antibody biomarkers. There has previously been no way to identify an antibody (a type of targeted immune molecule) without first knowing the antigen that triggers its production. The new study, however, challenges conventional wisdom and uses synthetic molecules rather than antigens to successfully detect signs of disease in patients' blood samples.
传统上，抗原——如从病毒或细菌，能够激发免疫反应的蛋白物质——一直以来都对抗体的生物标志物发现是非常必要的。以前有没有方法来识别的抗原没有事先知道触发其生产的抗体（有针对性的免疫分子型）。然而，这项新的研究挑战传统的智慧和运用合成分子而不是使用合成抗原，成功地检测出病人的血液样本中疾病的迹象。
These synthetic compounds have many advantages -- they can be modified easily and can be produced quickly in relatively large amounts at lower cost.
这些合成化合物具有很多优点——它们可以方便地进行修改，并且可以以较低的生产成本相对大量迅速。
"Dr. Kodadek has conceived of a new approach for identifying antibody biomarkers of human disease that bypasses the conventional, but difficult, step of identifying the natural antigens or antigen mimics," said James M. Anderson, M.D., Ph.D., director of the National Institutes of Health (NIH) Division of Program Coordination, Planning, and Strategic Initiatives, who helps oversee the NIH Common Fund's Pioneer Award Program. "The results in the paper suggest great potential for using this approach to rapidly develop diagnostic biomarkers for a variety of significant human diseases. Such boldness to challenge conventional paradigms to achieve important scientific advances is a hallmark of the NIH Director's Pioneer Award Program, which supported much of this research."
“博士Kodadek已设想了一种新的方法——识别人类疾病的抗体，绕过传统的生物标志物，这确实很难，第一步就是查明天然抗原或抗原模仿体，”詹姆斯M安德森博士说，国家健康研究院（NIH）主任协调方案，规划和战略举措，谁帮助监督国家机构美国国立卫生研究院共同基金的先锋奖励计划。 “报纸上的研究结果表明使用这种方法来快速开发一个重要的人类多种疾病的诊断标志物。这种勇于挑战传统模式，实现重要的科学进步的巨大潜力是美国国立卫生研究院主任的先锋奖励计划，标志支持本研究。“
"This study essentially puts an end to the notion that the only way to pull a potentially useful antibody from blood samples is with a specific antigen," said Kodadek. "Because the antigen identification problem has proven to be so difficult, we decided to take it out of the equation."
“这项研究必须终止一个概念，只有这样，才能从具有特别抗原的血液样本中找到可能有用的抗体”Kodadek说。 “由于抗原识别问题已经被证明是如此艰难，我们决定采取的方程来。”
A Focus on the Immune System
一个免疫系统的焦点。
To test the concept, Kodadek and his colleagues used comparative screening of combinatorial libraries of synthetic molecules -- peptoids -- against serum samples obtained from mice with a multiple-sclerosis-like condition or healthy controls. Those synthetic molecules that retained more immunoglobulin (IgG), a major type of antibody, from the blood samples of the diseased animals were identified as potential agents for capturing diagnostically useful molecules. This worked well.
要测试的概念，Kodadek和他的同事们用组合库的合成分子的比较筛选——对血清样本从一个多硬化样的条件或健康对照组小鼠获得——peptoids。那些保留下来的患病动物的血液样本更免疫球蛋白（IgG抗体），合成分子被确定为代理商的诊断经费用于捕捉有用的分子。这行之有效。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-01-09 00:02
医学,生命科学网